Samsung Bioepis Is Latest To Move Ustekinumab Into Phase III

Joins A Slew Of Other Biosimilar Developers Jostling For Position On Stelara

 
• By Dave Wallace

Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.

Paper people odd one out
Samsung Bioepis has joined a large Phase III crowd on ustekinumab • Source: Alamy

More from Biosimilars

More from Products